Relmada Therapeutics Inc. (NASDAQ: RLMD)
$3.79
-0.0500 ( -1.30% ) 63.9K
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Market Data
Open
$3.79
Previous close
$3.84
Volume
63.9K
Market cap
$113.76M
Day range
$3.76 - $3.89
52 week range
$2.42 - $7.22
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 30, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
10-q | Quarterly Reports | 50 | May 08, 2024 |
def | Proxies and info statements | 5 | Apr 09, 2024 |